VJHemOnc is committed to improving our service to you

EBMT 2020 | Current treatment landscape of DLBCL

VJHemOnc is committed to improving our service to you

Edmund Waller

Edmund Waller, MD, PhD, FACP, Division of Hematology/Oncology, Emory Clinic, Atlanta, GA, explores the current treatment landscape of diffuse large B-cell lymphoma (DLBCL), and discusses future approaches being developed, including earlier infusion of CAR T-cell therapies as evaluated in the BELINDA (NCT03570892) and TRANSFORM (NCT03575351) studies. Dr Waller also discusses polatuzumab vedotin, an antibody-drug conjugate that displays increased remission rates in relapsed/refractory lymphoma patients when compared to salvage bendamustine/rituximab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter